Truist Financial Maintains Medpace(MEDP.US) With Hold Rating, Announces Target Price $300
William Blair Maintains Medpace(MEDP.US) With Hold Rating
Baird Maintains Medpace(MEDP.US) With Hold Rating, Cuts Target Price to $313
Medpace Hldgs Analyst Ratings
Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $300
Deutsche Bank Adjusts Medpace Holdings Price Target to $270 From $280, Maintains Hold Rating
Truist Financial Maintains Medpace(MEDP.US) With Hold Rating
Medpace Hldgs Analyst Ratings
TD Cowen Remains a Hold on Medpace Holdings (MEDP)
William Blair Initiates Medpace(MEDP.US) With Hold Rating
Medpace Holdings: Strong Q1 Performance and Strategic Moves Justify Buy Rating
TD Cowen Downgrades Medpace(MEDP.US) to Hold Rating, Cuts Target Price to $328
TD Cowen Downgrades Medpace Holdings to Hold From Buy, Adjusts Price Target to $328 From $370
Medpace Holdings: Hold Rating Amid Biotech Funding Challenges and Regulatory Uncertainties
Truist Financial Maintains Medpace(MEDP.US) With Hold Rating, Announces Target Price $333
Medpace Holdings Is Maintained at Hold by Truist Securities
Medpace Holdings Price Target Cut to $333.00/Share From $347.00 by Truist Securities
Mizuho Securities Maintains Medpace(MEDP.US) With Buy Rating, Announces Target Price $355
Medpace Hldgs Analyst Ratings
Mizuho Maintains Outperform on Medpace Hldgs, Lowers Price Target to $355